Literature DB >> 10488967

Effect of apo E phenotype on plasma postprandial triglyceride levels in young male adults with and without a familial history of myocardial infarction: the EARS II study. European Atherosclerosis Research Study.

J Dallongeville1, L Tiret, S Visvikis, D S O'Reilly, M Saava, G Tsitouris, M Rosseneu, G DeBacker, S E Humphries, U Beisiegel.   

Abstract

The goal of the present study was to assess whether the effect of the apolipoprotein E polymorphism on postprandial lipemia explained part of the risk attributable to familial history of coronary heart disease. Cases (n = 407) were students, aged between 18 and 28 years, whose fathers had a proven myocardial infarction before the age of 55 years. Age-matched controls (n = 415) were recruited from the corresponding student registers. Blood was obtained after an overnight fast and at 2, 3, 4 and 6 h after ingestion of a fatty meal for triglyceride measurements. Apolipoprotein E phenotype was associated with postprandial triglyceride variability in both cases and controls. However, the apolipoprotein E-dependent triglyceride response was not significantly heterogeneous between cases and controls. In the pooled data, postprandial triglyceride levels were higher in carriers of the E2 and, to a lesser extent, of the E4 isoform, than in E3/3 homozygotes, independently of fasting triglyceride levels. At 6 h, triglyceride levels were increased by 21.2% (P < 0.01) in E2 carriers and 11.5% (P = 0.053) in E4 carriers by comparison to E3/3 subjects. These effects were not significantly different between regions. In conclusion, the effects of the apolipoprotein E polymorphism on postprandial triglyceridemia are similar across regions of Europe, and homogeneous in healthy young subjects with and without a family history of early myocardial infarction. This suggests that the influence of apolipoprotein E on myocardial infarction risk may be acting through mechanisms other than through effects on postprandial triglyceridemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10488967     DOI: 10.1016/s0021-9150(99)00069-6

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

Review 1.  Postprandial lipemia and coronary risk.

Authors:  W Patsch; H Esterbauer; B Föger; J R Patsch
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

Review 2.  Postprandial lipemia and cardiovascular disease.

Authors:  Dianne Hyson; John C Rutledge; Lars Berglund
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

3.  Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.

Authors:  Marguerite R Irvin; Edmond K Kabagambe; Hemant K Tiwari; Laurence D Parnell; Robert J Straka; Michael Tsai; Jose M Ordovas; Donna K Arnett
Journal:  Circ Cardiovasc Genet       Date:  2010-08-21

4.  Endothelial dysfunction and hypertension in obstructive sleep apnea - Is it due to intermittent hypoxia?

Authors:  Behrouz Jafari; Vahid Mohsenin
Journal:  J Cardiovasc Dis Res       Date:  2013-06-18

5.  Quantile-dependent expressivity of postprandial lipemia.

Authors:  Paul T Williams
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

6.  Effect of milk fat on LDL cholesterol and other cardiovascular risk markers in healthy humans: the INNOVALAIT project.

Authors:  Jean-Marie Bard; Ludovic Drouet; Denis Lairon; Murielle Cazaubiel; Corinne Marmonier; Ewa Ninio; Claire Bal Dit Sollier; Jean-Charles Martin; Constance Boyer; Christine Bobin-Dubigeon
Journal:  Eur J Clin Nutr       Date:  2019-11-11       Impact factor: 4.016

7.  Influence of Apolipoprotein E on the Lipid Profile and Postprandial Triglyceride Levels in Brazilian Postmenopausal Women With Artery Disease.

Authors:  Lúcia Helena Bonalume Tácito; Lilian Nakachima Yamada; Marcela Augusta de Souza Pinhel; Juan Carlos Yugar-Toledo; Dorotéia Rossi Silva Souza
Journal:  Clin Med Insights Cardiol       Date:  2017-09-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.